|
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, New JerseyTwo HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs makers.
|
|
|
Merck's Antiretroviral Isentress More Efficient In Suppressing HIV
Related Articles Merck's antiretroviral drug Isentress suppresses levels of HIV in previously untreated patients better than the company's antiretroviral efavirenz, according to research presented Sunday at a meeting of the American Society...
|
|
|
Newer HIV drugs found to be more tolerable for many
TRENTON, New Jersey Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs makers.
|
|
|
HIV Drugs Also Help New Patients
TRENTON, N.J.- Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well with new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs'...
|
|
|
Newer HIV drugs may be more easily tolerated
TRENTON, N.J.- Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs makers.Late...
|
|
|
Studies: Newer HIV drugs more tolerable for many
Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers.Late-stage, company...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.(AP) Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs makers....
|
|
|
Newer HIV drugs more tolerable
> TRENTON, New Jersey (AP) Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, New Jersey-Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers....
|
|
|
New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (Raltegravir) Reduced HIV
In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.- Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers.
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.(AP) - Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs'...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.(AP) Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers....
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.- Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers.
|
|
|
Studies: Newer HIV drugs more tolerable for many
Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers.Late-stage,...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, New Jersey (AP) - Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs'...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, New Jersey-Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers....
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs' makers.Late...
|
|
|
Studies: Newer HIV drugs more tolerable for many
NEW YORK (Associated Press) - Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs...
|
|
|
Studies: Newer HIV drugs more tolerable for many
- 1:08 p.m.TRENTON, N.J. (AP) - Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to...
|
|
|
Studies: Newer HIV drugs more tolerable for many
TRENTON, N.J.(AP) -- Two HIV drugs approved last year for patients who have developed resistance to older drugs also work well in new patients, and with fewer troubling side effects than a widely used regimen, according to the drugs'...
|
|
|
New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (raltegravir) Reduced HIV
In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected...
|
|
|
New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (raltegravir) Reduced HIV
In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected...
|
|
|
New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (raltegravir) Reduced HIV
WASHINGTON (Business Wire) -- In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated ...
|
|
|
Funding of drugs: do vaccines warrant a different approach?
The Lancet Infectious Diseases, Current Issue, Volume 8, Number 11, November 2008 The Lancet Infectious Diseases 2008; 8:727-733 Personal View Dr Philippe Beutels PhD a b , Prof Paul A Scuffham PhD c and Prof C Raina MacIntyre PhD d Summary...
|
